Getgoal Duo 1

Google Duo is a free, simple video calling app that brings you face-to-face with the people who matter most.

Getgoal duo 1. Lantus(R) is the No.1 leading basal insulin product in the world, and the results from GetGoal Duo 1 show that adding lixisenatide to treatment with Lantus(R) can offer significant benefits to patients." "Lixisenatide is a promising new GLP-1 agonist with a mode of action which complements that of basal insulin. It’s free, simple and works on Android phones, iPhones, tablets, computers, and. The hazard ratio for the primary end point in the lixisenatide group as compared with the placebo group was 1.02 (95% confidence interval CI, 0. to 1.17);.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Patients in the iGlarLixi arm of LixiLan‐O were to start treatment at an iGlar dose of 10 U. The results of the study showed that lixisenatide brings the combined benefit of HbA1c management in line with bolus insulins but with weight reduction as opposed to the usual weight gain and with lower risk of.

Liraglutide was uptitrated from 0·6 mg/day in week 1, to 1·2 mg/day in week 2, and then to 1·8 mg/day in week 3. Further, positive top-line results have been reported from the Phase III GetGoal Duo 1 study (also known as EFC*) supporting in particular the efficacy and safety of lixisenatide for use in. The GetGoal-Duo 1 study assessed the complementary action of lixisenatide and insulin glargine in patients with type 2 diabetes failing on oral antidiabetes medication.

Simultaneous or Sequential Combination:LixiLan-O and GetGoal DUO-1 Trials. ZEAL) informs that a total of 12 additional oral and poster presentations as well as 3 abstract presentations relating to lixisenatide (Lyxumia) will be given by Sanofi (EURONEXT. Further results are expected in 12.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). RIDDLE, MD 1 THOMAS FORST, MD 2 RONNIE ARONSON, MD, FRCPC, FACE 3 LEOBARDO SAUQUE-REYNA, MD 4 ELISABETH SOUHAMI, MD 5 LOUISE SILVESTRE, MD 5 LIN PING, MD 6 JULIO ROSENSTOCK, MD 7 OBJECTIVEdWhen oral therapy for type 2 diabetes is ineffective, adding basal insulin. Advancing Basal Insulin Glargine with Prandial Lixisenatide QD vs Insulin Glulisine QD or TID in T2DM:.

Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes:. Patients in GetGoal-Duo 1 were from 25 countries and were inadequately controlled (HbA1c 53–86 mmol/mol 7.0–10.0%) on existing OAD therapy. GetGoal DUO 2 follows the studies GetGoal-L and GetGoal DUO 1 , which have both explored the efficacy and safety of once-a-day add-on of lixisenatide to basal insulin at fixed dose , or to insulin glargine with continuing titration as compared to placebo.

Once-daily lixisenatide added on to consistently titrated insulin glargine plus oral agents in type 2 diabetes:. Copenhagen, 16:09 CEST (GLOBE NEWSWIRE) -- Further to a separate press release today on data presented from the GetGoal Duo 1 and GetGoal-L Phase III studies , Zealand Pharma A/S (NASDAQ OMX Copenhagen:. GetGoal Duo 1 Study In the GetGoal Duo 1 study reported by Julio Rosenstock, MD, Director, Dallas Diabetes and Endocrine Center, Texas, targeting PPG glucose with the GLP-1 agonist in patients with uncontrolled type 2 diabetes significantly improved HbA1c levels and reduced PPG level, without affecting weight.

In GetGoal DUO 2, the head-to-head comparison was between lixisenatide 1/d vs glulisine either 1/d (at the main meal, basal-plus) or 3/d (basal-bolus). Positive topline results of GetGoal Duo1 demonstrated the efficacy and safety of lixisenatide in combination with insulin glargine in patients with type 2 diabetes uncontrolled on oral anti-diabetics (OADs) – mainly metformin. Dulaglutide was started at the full 1·5 mg once-weekly dose.

Therefore, propensity score matching was used to indirectly compare simultaneous administration of iGlarLixi in the LixiLan-O trial (n=469) with sequential therapy, starting with initial insulin glargine 100 U/mL therapy for 12 weeks, followed by addition of lixisenatide in the GetGoal Duo-1 trial in patients with Type 2 diabetes mellitus who. GETGOAL-L-Asia GETGOAL-Duo-1 Cardiovascular outcome trials for GLP-1 RAs. GetGoal Duo 1 and GetGoal-L both achieved the primary efficacy endpoint of HbA1c improvement with an associated significant reduction in PPG.

Riddle MC, Forst T, Aronson R et al. GetGoal-Duo-1, a total of 22.4% of patients experienced symptomatic hypoglycemia with lixisenatide versus 13.5% for placebo 71. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. Patients received insulin glargine for a 12-week run-in period, followed by randomized Lyxumia or placebo for 24 weeks. To date, GetGoal-X, GetGoal-L, GetGoal-L Asia, GetGoal-Mono, GetGoal-S, GetGoal-F1 and GetGoal Duo 1 (also known as EFC*) have reported positive top-line results supporting potential efficacy and safety for lixisenatide.

If present, SU therapy was discontinued, and patients were initiated on basal insulin therapy with or without MET or a TZD during the run-in phase. Patients in GetGoal-Duo 1 were from 25 countries and were inadequately controlled (HbA1c 53–86 mmol/mol 7.0–10.0%) on existing OAD therapy. The originality of GetGoal DUO 2 is the comparison between add-on of lixisenatide and active treatment (prandial insulin).

The full study results from GetGoal Duo 1 are planned to be presented at a future medical congress. The GetGoal Duo-2 Evidence-Based Trial (NCT). A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) MATTHEW C.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. RIDDLE, MD 1 THOMAS FORST, MD 2 RONNIE ARONSON, MD, FRCPC, FACE 3 LEOBARDO SAUQUE-REYNA, MD 4 ELISABETH SOUHAMI, MD 5 LOUISE SILVESTRE, MD 5 LIN PING, MD 6 JULIO ROSENSTOCK, MD 7 OBJECTIVEdWhen oral therapy for type 2 diabetes is ineffective, adding basal insulin. Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

A 24-week, randomized, placebo-controlled study. Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. PS 063 GLP-1 based therapies Berlin 12 Poster Hall 3.

Mechanisms and Clinical Efficacy of Lixisenatide for the. The GetGoal program was initiated in May 08. Try Duo for web Try Duo Be together in the moment with Google Duo.

So far, GetGoal-X, GetGoal-L, GetGoal-L Asia, GetGoal-Mono, GetGoal-S, GetGoal-F1 and GetGoal Duo 1 have reported positive top-line results. Duo is the highest quality 1 video calling app. GetGoal Duo 1 was a randomized, double-blind, placebo-controlled study.

Prandial Options to Advance Basal Insulin Glargine Therapy:. To conduct two exploratory analyses to compare indirectly the efficacy and safety of simultaneous administration of insulin glargine 100 U (iGlar) and the glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide (Lixi) as a single-pen, titratable, fixed-ratio combination (iGlarLixi LixiLan trials) vs sequential administration of iGlar + Lixi (GetGoal Duo trials) in people with. Sanofi reported positive data from the the GetGoal Duo 1 and GetGoal L studies evaluating the once-daily GLP-1 agonist lixisenatide (Lyxumia®).

GetGoal‐P was a phase III, placebo‐controlled study investigating the efficacy and safety of lixisenatide once daily as add‐on therapy to pioglitazone with or without metformin. Sanofi) and OADs. October 12 12:00 - 13:00.

In GetGoal Duo 1, lixisenatide in combination with insulin glargine achieved the primary study endpoint of significantly reducing HbA1c with a significant improvement in 2-hour post-prandial. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. The main objective of this study was to assess the efficacy of lixisenatide once daily on glycaemic control in comparison with placebo in patients with T2DM as an.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

The abstract is titled:. Lixisenatide improved HbA1c, weight with standard GLP-1 safety profile PHILADELPHIA — Once-daily lixisenatide, an investigational GLP-1 agonist, was associated with significant HbA1c. Patients were given a prefilled syringe (dulaglutide) or pen (liraglutide) to be self-administered.

Results showed that lixisenatide caused mild and transient nausea and vomiting, the most common adverse events, and a limited additional or comparable risk of hypoglycemia. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J. GetGoal Duo 1 was a randomized, double-blind, multicenter study assessing the efficacy and safety of lixisenatide compared to placebo in combination with Lantus (insulin glargine;.

The GLP-1 RA, lixisenatide, has been studied in over 40 clinical trials and has shown significant beneficial effects on HbA1c reduction and 2-h PPG in numerous settings, including when used as. Shorter Time to Glycemic Control With IGlarLixi vs Gla-100:. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

The studies, in a total of nearly 1,500 patients. "During a 12-week run-in phase,. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

In GetGoal Duo‐1, for patients who had newly initiated iGlar, titrated to a fasting SMPG of 4.4 to 5.6 mmol/L (80‐100 mg/dL), during run‐in, the mean ± SD iGlar dose at baseline was 48 ± 22 U for the iGlar + Lixi arm. Like in 4B, in GetGoal DUO 2 the A1C decreased to similar values with lixisenatide or glulisine 1/d (~7.2%), or glulisine 3/d (~7.0%). A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

A 24-Week, Randomized, Placebo-Controlled Study (GETGOAL-DUO-1) MATTHEW C. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. Again, as in the 4B, body weight and hypoglycemia incidence. The upper boundary of the 95%.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). GETGOAL GLP-1 agonist AVE0010 in patients with type 2 diabetes mellitus for glycaemic control and safety evaluation (lixisenatide, µg once daily), GLP-1 RA glucagon-like peptide-1 receptor agonist,. After a 12-week run-in phase in which insulin glargine was initiated, patients with A1C ≥7% were randomized to μg lixisenatide ( n = 223) or placebo ( n = 223) for 24 weeks while continuing on insulin glargine.

The GetGoal Duo 1 study evaluated once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes. The GetGoal Duo-2 Trial. RIDDLE THOMAS FORST RONNIE ARONSON FRCPC FACE LEOBARDO SAUQUE-REYNA ELISABETH SOUHAMI LOUISE SILVESTRE LIN PING JULIO ROSENSTOCK A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) OBJECTIVEdWhen oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control.

If present, SU therapy was discontinued, and patients were initiated on basal insulin therapy with or with-out MET or a TZD during the run-in phase. Adding once-daily Lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. Group call with 32 participants today.

The GetGoal program started in May 08 and has enrolled more than 4,500 patients. Simultaneous or Sequential Combination:LixiLan-O and GetGoal DUO-1 Trials (cont) Simultaneous or Sequential Combination:LixiLan-L and GetGoal Duo-2 Trials. GetGoal Duo 1 is a randomized, double-blind, multicenter study, assessing the efficacy and safety of lixisenatide, compared to placebo, in combination with insulin glargine and OADs (mostly.

The GetGoal Duo 2 study is the first trial to directly compare lixisenatide with prandial insulin in combination with basal insulin.